Total Payments
$19,630
2024 Payments
$13,250
Companies
36
Transactions
257
Payment Breakdown by Category
Consulting$12,150 (61.9%)
Food & Beverage$7,006 (35.7%)
Education$474.10 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,150 | 5 | 61.9% |
| Food and Beverage | $7,006 | 245 | 35.7% |
| Education | $474.10 | 7 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fennec Pharmaceuticals, Inc. | $12,823 | 11 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $768.41 | 26 | $0 (2024) |
| Amgen Inc. | $661.43 | 18 | $0 (2022) |
| Genentech USA, Inc. | $488.27 | 30 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $470.77 | 26 | $0 (2023) |
| Eli Lilly Export S.A. Puerto Rico Branch | $443.52 | 15 | $0 (2022) |
| ABBVIE INC. | $406.16 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $388.78 | 18 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $318.37 | 12 | $0 (2018) |
| Celgene Corporation | $283.45 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,250 | 15 | Fennec Pharmaceuticals, Inc. ($12,823) |
| 2023 | $302.84 | 7 | ADC Therapeutics America, Inc. ($119.97) |
| 2022 | $1,011 | 27 | Eli Lilly Export S.A. Puerto Rico Branch ($169.92) |
| 2021 | $2,316 | 86 | Janssen Pharmaceuticals, Inc ($378.25) |
| 2020 | $698.19 | 29 | Amgen Inc. ($160.88) |
| 2019 | $948.12 | 39 | Celgene Corporation ($210.99) |
| 2018 | $895.47 | 41 | Boehringer Ingelheim Pharmaceuticals, Inc. ($269.84) |
| 2017 | $209.29 | 13 | Genentech USA, Inc. ($160.76) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $166.01 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 10/31/2024 | Fennec Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,950.00 | General |
| 10/15/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $91.91 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 10/11/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 10/01/2024 | Fennec Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,950.00 | General |
| 10/01/2024 | Fennec Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,950.00 | General |
| 09/26/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 08/28/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $136.81 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 08/07/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $122.00 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 08/05/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $107.95 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Fennec Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,950.00 | General |
| 07/11/2024 | Janssen Pharmaceuticals, Inc | ERLEADA (Drug), DARZALEX, TALVEY | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 05/23/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $118.71 | General |
| Category: DESMOID TUMORS | ||||||
| 04/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $75.25 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $136.07 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 08/10/2023 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $98.31 | General |
| Category: Cardiac Rhythm Management | ||||||
| 07/22/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $119.97 | General |
| 06/27/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.18 | General |
| Category: Oncology | ||||||
| 06/22/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.28 | General |
| Category: Hematology | ||||||
| 06/14/2023 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Hematology | ||||||
| 05/03/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.42 | General |
| Category: Oncology | ||||||
| 03/14/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.63 | General |
| 10/12/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2022 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Oncology | ||||||
| 10/08/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
About Dr. Veronica Vestal, MD
Dr. Veronica Vestal, MD is a Internal Medicine healthcare provider based in Toa Baja, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2013. The National Provider Identifier (NPI) number assigned to this provider is 1437593100.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Veronica Vestal, MD has received a total of $19,630 in payments from pharmaceutical and medical device companies, with $13,250 received in 2024. These payments were reported across 257 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($12,150).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Toa Baja, PR
- Active Since 04/24/2013
- Last Updated 04/24/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1437593100
Products in Payments
- Pedmark (Drug) $1,023
- Kyprolis (Drug) $359.42
- ERLEADA (Drug) $346.14
- GILOTRIF (Drug) $318.37
- OPDIVO (Biological) $314.35
- DARZALEX (Biological) $297.46
- Revlimid (Drug) $283.45
- TECENTRIQ (Biological) $209.35
- VERZENIO (Drug) $194.87
- CYRAMZA (Drug) $191.18
- VENCLEXTA (Drug) $188.86
- Lenvima (Drug) $144.56
- GAZYVA (Biological) $141.34
- Blincyto (Biological) $136.36
- XTANDI (Drug) $131.99
- Yescarta (Drug) $128.77
- Tavalisse (Drug) $124.86
- OGSIVEO (Drug) $118.71
- TAGRISSO (Drug) $111.04
- ELAHERE (Drug) $107.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.